Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Cross Above Fifty Day Moving Average of $0.45

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Rating) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.45 and traded as high as $0.80. Bellicum Pharmaceuticals shares last traded at $0.80, with a volume of 83,291 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. LADENBURG THALM/SH SH downgraded shares of Bellicum Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, March 15th. initiated coverage on shares of Bellicum Pharmaceuticals in a research note on Wednesday. They issued a “sell” rating for the company.

Bellicum Pharmaceuticals Stock Down 1.0 %

The firm’s 50 day moving average is $0.45 and its two-hundred day moving average is $0.82.

Hedge Funds Weigh In On Bellicum Pharmaceuticals

A hedge fund recently raised its stake in Bellicum Pharmaceuticals stock. Susquehanna International Group LLP boosted its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Rating) by 42.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,310 shares of the biopharmaceutical company’s stock after purchasing an additional 12,616 shares during the quarter. Susquehanna International Group LLP owned about 0.49% of Bellicum Pharmaceuticals worth $30,000 at the end of the most recent reporting period. 28.66% of the stock is owned by hedge funds and other institutional investors.

About Bellicum Pharmaceuticals

(Get Rating)

Bellicum Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.

Featured Articles

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with's FREE daily email newsletter.